This report contains market size and forecasts of NGS Services in China, including the following market information:
China NGS Services Market Revenue, 2016-2021, 2022-2027, ($ millions)
China top five NGS Services companies in 2020 (%)
The global NGS Services market size is expected to growth from US$ XX million in 2020 to US$ XX million by 2027; it is expected to grow at a CAGR of XX% during 2021-2027.
The China NGS Services market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.
QYResearch has surveyed the NGS Services Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
China NGS Services Market,
China NGS Services Market Segment Percentages,
RNA-Seq
Exome
China NGS Services Market,
China NGS Services Market Segment Percentages,
Oncology
Lung cancer
Breast cancer
Prostate cancer
Colorectal cancer
Others
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies NGS Services revenues in China market, 2016-2021 (Estimated), ($ millions)
Key companies NGS Services revenues share in China market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
Beijing Genomics Institute (BGI)
Cegat (Centre for Genomics and Transcriptomics) GMBH
DNA Vision SA
Eurofins Genomics Inc.
Febit / Comprehensive Biomarker Center GMBH (CBC)
Genomnia SRL
Mina Inc.
Macrogen Inc.
Microsynth AG
Seqomics
Source Bio Science
China NGS Services Market Revenue, 2016-2021, 2022-2027, ($ millions)
China top five NGS Services companies in 2020 (%)
The global NGS Services market size is expected to growth from US$ XX million in 2020 to US$ XX million by 2027; it is expected to grow at a CAGR of XX% during 2021-2027.
The China NGS Services market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.
QYResearch has surveyed the NGS Services Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
China NGS Services Market,
By Type
, 2016-2021, 2022-2027 ($ Millions)China NGS Services Market Segment Percentages,
By Type
, 2020 (%)RNA-Seq
Exome
China NGS Services Market,
By Application
, 2016-2021, 2022-2027 ($ Millions)China NGS Services Market Segment Percentages,
By Application
, 2020 (%)Oncology
Lung cancer
Breast cancer
Prostate cancer
Colorectal cancer
Others
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies NGS Services revenues in China market, 2016-2021 (Estimated), ($ millions)
Key companies NGS Services revenues share in China market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
Beijing Genomics Institute (BGI)
Cegat (Centre for Genomics and Transcriptomics) GMBH
DNA Vision SA
Eurofins Genomics Inc.
Febit / Comprehensive Biomarker Center GMBH (CBC)
Genomnia SRL
Mina Inc.
Macrogen Inc.
Microsynth AG
Seqomics
Source Bio Science
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.